Abstract: Protein constructs comprising a BTNL 3/8 targeting moiety, a payload and an optional linker are described herein. Pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.

Abstract: The present disclosure provides compositions and methods for engineering ?? T cells (e.g., v?1 T cells and v?2 T cells) with an IL-15 receptor ? subunit (IL-15R?), e.g., by transduction with a viral vector, to restore IL-15 responsiveness. Further provided are populations of engineered ?? T cells and methods of using the same.

Abstract: Some aspects of the present disclosure are directed to engineered innate lymphoid cells comprising a heterologous targeting construct specific for mesothelin and uses thereof. Some aspects of the present disclosure are directed to polynucleotides encoding a chimeric antigen receptor (CAR) that specifically binds human mesothelin, host cells comprising the polynucleotide, and methods of treating a disease or condition in a subject using the same.

Abstract: The invention relates to methods for expanding ?? T cells comprising preparing a composition enriched for ?? T cells and culturing the composition in the presence of feeder cells. Also provided is a method for engineering ?? T cells comprising preparing a composition enriched for ?? T cells, transducing the composition to express a chimeric antigen receptor (CAR) specific for a tumour associated antigen and culturing the transduced composition to expand the engineered ?? T cells. Also provided are expanded and engineered ?? T cells produced according to the described methods, which find utility in adoptive T cell therapies, chimeric receptor therapies and the like.

Abstract: The invention relates to methods of treating myeloid malignancies by administering compositions comprising V?1+ T cells.

Abstract: The invention relates to compositions comprising NaturalKiller (NK) cells and ?? T cells, particularly for use in adoptive immunotherapy. The invention also provides method for preparing such compositions which comprises contacting a sample with an anti-TCR delta variable 1 (anti-V?1) antibody.

Abstract: The present invention provides methods of expanding ?? T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded ?? T cells and methods of using the expanded ?? T cells (e.g., a part of an adoptive T cell therapy).

Abstract: The invention relates to methods for the isolation of non-haematopoietic tissue-resident lymphocytes, particularly ?? T cells. Such ?? T cells include non-V?2 cells, e.g. V?1, V?3 and V?5 cells and such non-haematopoietic tissues include skin and gut. It will be appreciated that such isolated non-haematopoietic tissue-resident lymphocytes find great utility in adoptive T cell therapies, chimeric receptor therapies and the like. Also provided are methods for expanding isolated tissue-resident lymphocytes, particularly methods for isolating and expanding ?? T cells. The present invention also relates to both individual cells and populations of cells produced by the methods described herein.

Abstract: The invention relates to ex vivo methods of modulating gamma variable 4 (V?4) T cells using antibodies or fragments thereof, which specifically bind to a V?4 chain of a ?? T cell receptor (TCR) and not to a gamma variable 2 (V?2) chain of a ?? TCR. Methods of treatment and other uses of expanded populations of V?4 T cells produced by said methods are also provided.

Abstract: The invention relates to compositions comprising V?1+ T cells, for use in treating myeloid malignancies. The present invention also relates to methods of treatment using said compositions.

Abstract: This invention relates to the expansion of non-haematopoietic tissue-resident ?? T cells in vitro by culturing lympho-cytes obtained from non-haematopoietic tissue of humans or non-human animals in the presence of interleukin-2 (IL-2) and/or inter-leukin-15 (IL-15) and the absence of TCR activation or co-stimulation signals, without any direct contact with stromal or epithelial cells. Methods of non-haematopoietic tissue-resident ?? T cell expansion are provided, as well as populations of non-haematopoietic tissue-resident ?? T cells and uses thereof.

Abstract: The invention relates to anti-V?1 antibodies or fragments thereof for use in methods of treating a cancer, an infectious disease or an inflammatory disease in a subject in need thereof.

Abstract: The invention relates to ex vivo methods of modulating V?1 T cells using anti-V?1 antibodies or fragments thereof.

Abstract: The invention relates to a method for the isolation of lymphocytes (in particular ?? T cells) from a non-haematopoietic tissue sample comprising the steps of: culturing the non-haematopoietic tissue sample in the presence of (a) Interleukin-2 (IL-2) or Interleukin-9 (IL-9); (b) Interleukin-5 (IL-15); and (c) Interleukin-21 (IL-21); and collecting a population of lymphocytes cultured from the non-haematopoietic tissue sample. Methods of subsequent expansion are provided, as well as populations of isolated cells obtained by the method and uses thereof.

Abstract: The present invention relates to a method for the isolation of lymphocytes (in particular ?? T cells) from a non-haematopoietic tissue sample comprising the steps of culturing a non-haematopoietic tissue sample which is an intact biopsy obtained from a non-haematopoietic tissue in the presence of Interleukin-2 (IL-2) and Interleukin-15 (IL-15); and collecting a population of lymphocytes cultured from the non-haematopoietic tissue sample. Methods of subsequent expansion are provided, as well as populations of isolated cells obtained by the method and uses thereof.

Abstract: Protein constructs comprising a BTNL3/8 targeting moiety, a payload and an optional linker are described herein. Pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.

Abstract: The present invention provides methods of expanding ?? T cells from a non-haematopoietic tissue source. Further provided are compositions of expanded ?? T cells and methods of using the expanded ?? T cells (e.g., apart of an adoptive T cell therapy).

Abstract: The present invention provides engineered lymphocytes (e.g., ?? T cells, NK cells, NK-like T cells, engineered innate lymphoid cells, or MAIT cells) comprising a heterologous targeting construct lacking an intracellular signaling domain capable of activating the lymphocyte on which the construct is expressed. Further provided are compositions of engineered lymphocytes (e.g., ?? T cells) and methods of using the engineered lymphocytes (e.g., ?? T cells, e.g., a part of an adoptive T cell therapy).

Abstract: This invention relates to the expansion of non-haematopoietic tissue-resident ?? T cells in vitro by culturing lymphocytes obtained from non-haematopoietic tissue of humans or non-human animals in the presence of interleukin-2 (IL-2) and/or interleukin-15 (IL-15) and the absence of TCR activation or co-stimulation signals, without any direct contact with stromal or epithelial cells. Methods of non-haematopoietic tissue-resident ?? T cell expansion are provided, as well as populations of non-haematopoietic tissue-resident ?? T cells and uses thereof.